Pallas Capital Advisors LLC Invests $38,000 in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Pallas Capital Advisors LLC acquired a new stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 12,775 shares of the company’s stock, valued at approximately $38,000.

Other institutional investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its holdings in Organogenesis by 94.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,663 shares of the company’s stock valued at $27,000 after buying an additional 3,235 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Organogenesis by 11.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company’s stock valued at $145,000 after purchasing an additional 5,359 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Organogenesis in the 4th quarter valued at approximately $43,000. CWM LLC boosted its position in shares of Organogenesis by 301.8% during the second quarter. CWM LLC now owns 25,617 shares of the company’s stock worth $72,000 after buying an additional 19,242 shares during the period. Finally, Connors Investor Services Inc. lifted its position in shares of Organogenesis by 58.1% during the first quarter. Connors Investor Services Inc. now owns 68,000 shares of the company’s stock worth $193,000 after purchasing an additional 25,000 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Trading Up 1.1 %

Shares of Organogenesis stock traded up $0.03 during trading hours on Wednesday, reaching $2.72. The stock had a trading volume of 42,571 shares, compared to its average volume of 945,348. The company has a current ratio of 2.73, a quick ratio of 2.42 and a debt-to-equity ratio of 0.22. Organogenesis Holdings Inc. has a 1 year low of $1.96 and a 1 year high of $4.70. The firm has a 50 day simple moving average of $2.74 and a two-hundred day simple moving average of $2.85. The firm has a market capitalization of $360.60 million, a price-to-earnings ratio of 67.25 and a beta of 1.65.

Wall Street Analyst Weigh In

Separately, Lake Street Capital initiated coverage on Organogenesis in a research report on Friday, June 28th. They set a “buy” rating and a $5.00 price objective for the company.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.